JCR Pharma [4552] fell. Morgan Stanley MUFG Securities has downgraded its investment rating from 'overweight' to 'equal weight' and lowered its target stock price from 1700 yen to 590 yen. It is concerned that the catalyst for a major new drug will be difficult to maintain between 2026 and 2027, and that there may be a change in the partnership with Takeda regarding Izcargo. The view has changed to a delay in realizing profit growth through new drugs until the fiscal year ending March 2030.
JCRファーマ---反落、収益成長タイミング先送りとして米系証券が格下げ
JCR Pharma - downgraded by US securities as timing for revenue growth is delayed
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.